Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Boehringer Ingelheim
McKesson
US Department of Justice
Baxter
Queensland Health
Fuji
Cipla
Novartis
Colorcon

Generated: January 19, 2018

DrugPatentWatch Database Preview

Fondaparinux sodium - Generic Drug Details

« Back to Dashboard

What are the generic sources for fondaparinux sodium and what is the scope of fondaparinux sodium patent protection?

Fondaparinux sodium
is the generic ingredient in two branded drugs marketed by Mylan Ireland Ltd and Dr Reddys Labs Ltd, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are fourteen drug master file entries for fondaparinux sodium. Four suppliers are listed for this compound.
Pharmacology for fondaparinux sodium
Drug ClassFactor Xa Inhibitor
Mechanism of ActionFactor Xa Inhibitors

US Patents and Regulatory Information for fondaparinux sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Ireland Ltd ARIXTRA fondaparinux sodium INJECTABLE;SUBCUTANEOUS 021345-004 May 28, 2004 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mylan Ireland Ltd ARIXTRA fondaparinux sodium INJECTABLE;SUBCUTANEOUS 021345-002 May 28, 2004 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Dr Reddys Labs Ltd FONDAPARINUX SODIUM fondaparinux sodium INJECTABLE;SUBCUTANEOUS 091316-002 Jul 11, 2011 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Dr Reddys Labs Ltd FONDAPARINUX SODIUM fondaparinux sodium INJECTABLE;SUBCUTANEOUS 091316-001 Jul 11, 2011 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Dr Reddys Labs Ltd FONDAPARINUX SODIUM fondaparinux sodium INJECTABLE;SUBCUTANEOUS 091316-004 Jul 11, 2011 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mylan Ireland Ltd ARIXTRA fondaparinux sodium INJECTABLE;SUBCUTANEOUS 021345-001 Dec 7, 2001 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mylan Ireland Ltd ARIXTRA fondaparinux sodium INJECTABLE;SUBCUTANEOUS 021345-003 May 28, 2004 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Dr Reddys Labs Ltd FONDAPARINUX SODIUM fondaparinux sodium INJECTABLE;SUBCUTANEOUS 091316-003 Jul 11, 2011 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Medtronic
Harvard Business School
Moodys
US Department of Justice
Johnson and Johnson
Queensland Health
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot